What is the 13F Pro Quality Score for HROW?

13F Pro ranks HARROW, INC. (HROW) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HROW's current score at https://13fpro.ai/research/HROW (free sign-up required for the full ranking).

Which hedge funds own the most HROW stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of HROW include Opaleye Management, BlackRock,, Private Capital Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/HROW as soon as new 13F filings post.

Where does 13F Pro source HROW data?

All HARROW, INC. fundamentals and ownership data come directly from SEC EDGAR. HARROW, INC. files with the SEC under CIK 1360214. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HROW in?

HARROW, INC. (HROW) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HROW research updated on 13F Pro?

HROW's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

HARROW, INC.(HROW)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1360214 HROW stock profile & AI dashboard →

13F Pro Quality Score

41.6/100

Rank #1,885 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

88.7/100

Profitability

17.6/100

Balance Sheet

17.7/100

Earnings Quality

30.0/100

Free Cash Flow

66.3/100

Institutional Flow

20.1/100

Revenue Scale

25.8/100

Dilution Risk

27.2/100

HROW Stock Analysis & AI Quality Score

AI stock analysis and institutional research for HARROW, INC. (HROW), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HROW at 41.6/100 on a 32-signal composite quality model, placing it at rank #1,885 of 2,879 stocks — the bottom half of the AI-ranked universe. HROW scores in the top quartile across revenue growth (88.7). Areas of concern include profitability (17.6) and balance sheet strength (17.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), HARROW, INC. reports quarterly revenue of $44.2M, net income of $-27.6M, free cash flow of $-9.2M. Top institutional holders of HROW by reported 13-F value include Opaleye Management, BlackRock,, Private Capital Management,, based on the most recent SEC filings. HROW trades on the Nasdaq exchange and files with the SEC under CIK 1360214. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HROW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HARROW, INC. directly from SEC EDGAR. HARROW, INC.'s 13F Pro composite quality score has ranged between 8 and 80 since 2021, currently 41.6 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about HARROW, INC.

Quirks, history, and lore behind HROW — the kind of stuff that makes a stock memorable.

1
The Basics
A specialty pharmaceutical company · small-cap · listed on Nasdaq · headquartered in North Carolina.
2
The Numbers
Annual revenue in the range of roughly $100 million, with a focus on high-margin niche drugs rather than blockbuster volume.
3
The History
The company pivoted its strategy to focus on ophthalmology — eye care — acquiring a portfolio of FDA-approved products targeting diseases most big pharma ignores.
4
The Secret
Its business model leans heavily on commercializing underserved drugs — scooping up approved treatments that larger companies have abandoned or overlooked.
5
The Lore
One of its key products targets dry eye disease and ocular surface conditions — a space that sounds unglamorous until you realize millions of Americans stare at screens all day.
6
The Giveaway
This ophthalmic-focused pharma company trades under a ticker that sounds like something you'd do to a horse, and its name evokes a plow cutting a furrow — straight and narrow.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$44.2M

Net Income

Q1 2026

$-27.6M

Free Cash Flow

Q1 2026

$-9.2M

ROIC

Q1 2026

-6.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+36.4% YoY

$272.3MFY 2025

FY22 $88.6MFY23 $130.2MFY24 $199.6MFY25 $272.3M

Net Income

+70.6% YoY

$-5.1MFY 2025

FY22 $-14.1MFY23 $-24.4MFY24 $-17.5MFY25 $-5.1M

Operating Income

+245.9% YoY

$30.5MFY 2025

FY22 $1.9MFY23 $431.0KFY24 $8.8MFY25 $30.5M

EPS (Diluted)

+71.4% YoY

$-0.14FY 2025

FY22 $-0.51FY23 $-0.75FY24 $-0.49FY25 $-0.14

Total Assets

+2.7% YoY

$399.5MFY 2025

FY22 $157.4MFY23 $312.2MFY24 $389.0MFY25 $399.5M

Total Debt

-4.8% YoY

$250.0MFY 2025

FY22 $151.8MFY23 $246.7MFY24 $262.7MFY25 $250.0M

Op. Cash Flow

+297.6% YoY

$43.9MFY 2025

FY22 $1.7MFY23 $3.8MFY24 $-22.2MFY25 $43.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$272.3M +36.4%	$199.6M +53.3%	$130.2M +47.0%	$88.6M +22.2%	$72.5M +48.3%	$48.9M
Net Income	$-5.1M +70.6%	$-17.5M +28.4%	$-24.4M -73.3%	$-14.1M +21.8%	$-18.0M -436.4%	$-3.4M
Operating Income	$30.5M +245.9%	$8.8M +1946.9%	$431.0K -77.5%	$1.9M +18.9%	$1.6M +319.2%	$385.0K
EPS (Diluted)	$-0.14 +71.4%	$-0.49 +34.7%	$-0.75 -47.1%	$-0.51	—	$-0.13
Total Assets	$399.5M +2.7%	$389.0M +24.6%	$312.2M +98.4%	$157.4M +60.1%	$98.3M +71.1%	$57.5M
Total Debt	$250.0M -4.8%	$262.7M +6.5%	$246.7M +62.6%	$151.8M +47.3%	$103.0M +415.0%	$20.0M
Operating Cash Flow	$43.9M +297.6%	$-22.2M -678.2%	$3.8M +125.2%	$1.7M -66.5%	$5.1M +562.0%	$-1.1M

Get alerted when HROW's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HARROW, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HROW

Opaleye Management Inc.
$99.9M2,832,230 sh
BlackRock, Inc.
$90.0M2,552,759 sh
Private Capital Management, LLC
$55.1M1,562,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$49.5M1,403,056 sh
Luxor Capital Group, LP
$39.5M1,119,400 sh
STATE STREET CORP
$30.1M855,047 sh
GEODE CAPITAL MANAGEMENT, LLC
$30.0M852,034 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$24.9M705,000 sh
MARSHALL WACE, LLP
$22.7M644,918 sh
DIMENSIONAL FUND ADVISORS LP
$20.4M579,520 sh

Fund	Value	Shares
Opaleye Management Inc.	$99.9M	2,832,230
BlackRock, Inc.	$90.0M	2,552,759
Private Capital Management, LLC	$55.1M	1,562,000
VANGUARD CAPITAL MANAGEMENT LLC	$49.5M	1,403,056
Luxor Capital Group, LP	$39.5M	1,119,400
STATE STREET CORP	$30.1M	855,047
GEODE CAPITAL MANAGEMENT, LLC	$30.0M	852,034
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$24.9M	705,000
MARSHALL WACE, LLP	$22.7M	644,918
DIMENSIONAL FUND ADVISORS LP	$20.4M	579,520

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HROW on your watchlist

Track score changes the day HARROW, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HROW a good stock to buy?

13F Pro's AI-powered analysis of HARROW, INC. (HROW) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HROW are available on the HROW stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HROW?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HROW. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HARROW, INC.'s investment landscape.